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Aims To determine whether circulating levels of chromogranin A (CgA) provide prognostic information independently of
conventional risk markers in acute coronary syndromes (ACSs).
Methods
and results
We measured circulating CgA levels on day 1 in 1268 patients (median age 67 years, 70% male) with ACS admitted to
a single coronary care unit of a Scandinavian teaching hospital. The merit of CgA as a biomarker was evaluated after
adjusting for conventional cardiovascular risk factors. During a median follow-up of 92 months, 389 patients (31%)
died. The baseline CgA concentration was strongly associated with increased long-term mortality [hazard ratio per 1
standard deviation increase in logarithmically transformed CgA level: 1.57 (1.44–1.70), P , 0.001], heart failure hos-
pitalizations [1.54 (1.35–1.76), P , 0.001], and recurrent myocardial infarction (MI) [1.27 (1.10–1.47), P , 0.001],
but not stroke. After adjustment for conventional cardiovascular risk markers, the association remained signiﬁcant
for mortality [hazard ratio 1.28 (1.15–1.42), P , 0.001] and heart failure hospitalization [hazard ratio 1.24
(1.04–1.47), P ¼ 0.02], but not recurrent MI.
Conclusion CgA is an independent predictor of long-term mortality and heart failure hospitalizations across the spectrum of
ACSs and provides incremental prognostic information to conventional cardiovascular risk markers.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Acute coronary syndromes † Chromogranin A † Troponin T † Echocardiography † Prognosis
During the past decade, major progress has been made in the man-
agement of patients with acute coronary syndromes (ACSs). In
parallel with advances in medical therapy and increasing use of
an early invasive strategy, there has been focus on early risk stra-
tiﬁcation of patients, and in particular, the potential prognostic
utility of circulating biomarkers.
1 Currently, cardiac-speciﬁc tropo-
nins and B-type natriuretic peptide are the major routinely
measured circulating biomarkers in patients with ACSs.
2,3
Chromogranin A (CgA) is a 439 amino acid, 49 kDa polypeptide,
which has been identiﬁed throughout the endocrine and nervous
systems.
4 Markedly elevated plasma levels have been observed in
patients with neuroendocrine tumours,
5 such as pheochromocy-
toma
6 and carcinoid,
7 and the clinical application of CgA measure-
ments has so far been limited to diagnosis and follow-up of patients
with such tumours. However, circulating CgA levels also correlate
closely with increased sympathetic activity both in the adrenal
medulla and the peripheral nerve endings,
8–10 suggesting that cir-
culating CgA may integrate neuroendocrine signals from various
sources and thus represent an index of overall neuroendocrine
activity. Moreover, myocardial production of CgA in humans
with dilated and hypertrophic cardiomyopathy has recently been
demonstrated,
11 and CgA has been shown to increase in
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doi:10.1093/eurheartj/ehn513proportion to clinical severity and to be associated with prognosis
in patients with both chronic and post-infarction heart failure.
12,13
In a small population with predominantly ST-elevation myocardial
infarction (MI), we have previously reported a univariable associ-
ation between CgA levels and long-term survival,
14 but because
of modest study power, it remains unclear whether CgA is an inde-
pendent predictor of survival. In patients with unstable angina and
non-ST-elevation MI, no prognostic data are currently available.
Because increased neuroendocrine activity may be related to
potentially harmful pathophysiological processes in patients with
both ST-elevation and non-ST-elevation ACS, including endothelial
dysfunction and activation of pro-inﬂammatory cytokines, we
hypothesized that circulating CgA levels would be predictive of
the incidence of death and non-fatal cardiovascular events across
the spectrum of ACS and would provide prognostic information
independently of conventional risk markers, including objective
measures of left ventricular dysfunction and contemporary
cardiac biomarkers.
Methods
Study design
Patients with ACS, deﬁned as a diagnosis of unstable angina,
non-ST-elevation MI, or ST-elevation MI, admitted to the coronary
care unit (CCU) of the Sahlgrenska University Hospital, Gothenburg,
Sweden during the period mid-September 1995 to mid-March 2001,
were eligible for participation in a prospective risk stratiﬁcation pro-
gramme, PRACSIS (Prognosis and Risk in Acute Coronary Syndromes
in Sweden),
15 in which the main study exclusion criteria were age ,18
or  80 years, non-coronary artery disease associated with a life expect-
ancy ,1 year, residence outside the city of Gothenburg, unwillingness to
participate, and prior admission resulting in inclusion in the study.
During this 5.5-year period, a total of 2335 patients were included in
the PRACSIS programme. Until November 1995, only clinical infor-
mation was collected in PRACSIS and we did not perform consecutive
serum sampling, resulting in only six random morning pilot serum
samples being drawn in this period. Thereafter, serum for later analysis
was obtained the ﬁrst morning after admission to the CCU in the
patients who, at this stage, were assigned a diagnosis of ACS. Thus, a
number of patients were not eligible for blood sampling despite later
being considered as having ACS and noted as such. Another portion
of patients (n ¼ 612) in PRACSIS were transferred to the CCU from
an internal medicine ward where they had been admitted owing to an
initially uncertain ACS, or from the intensive care unit where they
were admitted owing to the need of mechanical ventilation. We lack
serum from a majority of these patients. Yet another portion of patients
did not survive until the ﬁrst morning in hospital or were at this time
undergoing angiography, and during some holidays serum sampling
was not attempted. These patients were included in the PRACSIS pro-
gramme, but not in the biomarker substudy. Users of proton pump
inhibitors on admission (n ¼ 38) were also excluded from this study,
as proton pump inhibitors are known to increase circulating CgA
levels.
16 Thus, the ﬁnal study group comprised 1268 patients.
The primary outcome measure was mortality from all causes. The
median follow-up for this primary endpoint was 92 (interquartile
range 71–110) months (until 1 January 2007). Survival conﬁrmation
and date of death were obtained from the Swedish National Popu-
lation Registry. Eleven patients, who emigrated from Sweden, were
lost to follow-up and censored at the day of emigration.
Pre-speciﬁed secondary outcome measures were the incidence of
the following separate morbidity endpoints: heart failure [International
Statistical Classiﬁcation of Disease, Ninth Revision (ICD-9) code 428
or ICD-10 code I50], acute MI (ICD-9 code 410 or ICD-10 code
I21 or I22), and stroke (ICD-9 codes 431, 432, 433, or 436 or
ICD-10 codes I61, I62, I63, or I64). These data were obtained from
the Swedish Hospital Discharge Register. Because of a slower conﬁr-
mation process than for mortality data, morbidity data were not
available after 31 December 2002. Accordingly, the median follow-up
period for morbidity data was 50 (interquartile range 32–65) months.
For quality control purposes, morbidity data from the Registry were
checked against information in the patients’ medical records by a
cardiologist (M.H.) blinded to biomarker results. No patient was
excluded owing to missing data for outcome.
Patients were prospectively classiﬁed according to Killip class on
admission and during the index hospitalization. Electrocardiographic
ﬁndings on admission were classiﬁed according to the presence or
absence of ST-segment elevation and ST-segment depression. On
the basis of hospital records and personal interview, patients were
classiﬁed as having or not having a history of MI, angina pectoris,
chronic heart failure, diabetes mellitus, or hypertension. The study
protocol was approved by the Regional Ethics Committee before
the initiation of the study. Informed consent was obtained from all
participating patients.
Blood sampling procedures
and echocardiography
Peripheral venous blood was obtained within 24 h of admission by
direct venipuncture of an antecubital vein after the patients had been
supine for .30 min. Blood samples for CgA determination were
drawn into serum tubes and centrifuged within 1 h. Blood samples for
the determination of pro-B-type natriuretic peptide (proBNP) were
drawnintopyrogen-freetubeswithEDTAasanticoagulant,immediately
immersed in ice water, and centrifuged within 1 h.
All serum samples were stored at 2708C pending analysis. Plasma
and serum samples had been thawed twice prior to CgA analysis.
However, CgA is considered to be stable in vitro at room temperature
and plasma levels are not inﬂuenced by repeated thawing–refreezing
cycles.
17 Echocardiographic investigation was performed by an experi-
enced investigator within 5 days of hospital admission, as described
previously.
18,19
Biochemical analyses
CgA in serum was measured by a commercially available ELISA assay
(code K0025, DakoCytomation, Glostrup, Denmark). The detection
limit of the assay was 7.0 U/L, and the intra- and interassay coefﬁcients
of variance were ,5 and 10%, respectively. According to the manufac-
turer, the upper reference limit is 18 U/L. Troponin T and creatine
kinase MB fraction in serum were measured on a modular platform
(Roche Diagnostics, Mannheim, Germany). Troponin T levels were
unavailable in 225 subjects, as troponin T measurement was not part
of the clinical routine during the ﬁrst inclusion period. ProBNP3–108
was measured using immunoﬂuorescent assays calibrated with spiked
plasma (Biosite Inc., San Diego, CA, USA).
20 The minimal detectable
concentration was 400 ng/L and the upper range 30 000 ng/L. All
samples were run in duplicate in a blinded fashion. Creatinine and
total cholesterol concentrations in serum were determined by
routine laboratory methods. Creatinine clearance rate (mL/min) was
estimated (estimated glomerular ﬁltration rate, eGFR) using the Cock-
croft–Gault formula,
21 as [(1402age)   weight (kg)/serum creatinine
(mmol/L)] multiplied by a constant of 1.23 in men and 1.04 in women.
A.M. Jansson et al. 26Statistical methods
Categorical variables were reported as proportions and continuous
variables as median or mean values. The association between CgA
and baseline demographic variables and cardiovascular risk factors was
assessed by the Mann–Whitney U test and Spearman rank correlation
(rs) for categorical and continuous variables, respectively. To visualize
the relationship between CgA quartiles and mortality, Kaplan–Meier
plots were generated. Cox proportional hazards regression analyses
were used to calculate crude and adjusted risk estimates associated
with a 1 standard deviation (SD) increase in logarithmically transformed
CgA levels for the primary endpoint: mortality from all causes, as well as
for the following individual secondary endpoints: hospitalizations for
heart failure, recurrent MI, and stroke. Adjustments were made for
the following confounders: age (continuous), gender, index diagnosis,
smoking status, prior MI, angina pectoris, diabetes, hypertension,
heart failure, Killip class (dichotomous, i.e. cutoff Killip class .1),
eGFR (continuous, logarithmically transformed), heart rate (continuous,
logarithmically transformed), and peak creatine kinase-MB (continuous,
logarithmically transformed). In addition, adjustments were also made
for troponin T, left ventricular ejection fraction, and proBNP (all
continuous and logarithmically transformed) in the cohorts where
such measurements were available.
The assumption of proportional hazards was assessed by studying
whether interaction terms between the logarithm of time and covari-
ates signiﬁcantly improved the 22 log-likelihood of the model. The
assumption was met for all variables in all models, except for the end-
point rehospitalization owing to heart failure, where previous MI and
creatine kinase-MB showed a slight non-proportionality in the total
cohort, and index diagnosis and creatine kinase-MB in the cohort
with troponin T measurements available. Inclusion of the time-
dependent covariates into the corresponding models above resulted
in only minor changes of the hazard ratios for CgA. We therefore
decided to use the original models in order to cohere with our pub-
lished reports on other markers from the same cohorts and to
adjust for the same covariates in the different endpoint analyses.
Similarly, the assumption of linearity for continuous variables was
checked by entering the squared transformations of the variables
into the models. A signiﬁcant change in the 22 log-likelihood for
any model was considered a sign of non-linearity. All variables met
the assumption of linearity in all models, except for age, regarding
the endpoint rehospitalization owing to MI in the total cohort and
regarding rehospitalization owing to stroke in the three other
cohorts. Also, eGFR showed sign of non-linearity regarding heart
failure in the cohort where troponin T, ejection fraction, and
proBNP were available. For these models, we analysed the hazard
ratios for CgA when the corresponding transformations were
entered into the model, which resulted in only small changes from
the original models, and, for the same reasons as for non-
proportionality, we decided to use the models without squared
transformation of these covariates.
Our primary objective variable CgA did not show any sign of
non-proportionality or non-linearity.
Hazard ratios are given with 95% conﬁdence intervals. All P-values
are two-tailed and considered signiﬁcant if ,0.05.
Results
Baseline characteristics
A total of 1268 patients (median age 67 years, 70% male) had
blood samples for CgA determination obtained within 24 h of
admission and were not users of proton pump inhibitors at the
time of admission. The baseline characteristics of patients accord-
ing to CgA quartiles are presented in Table 1, where also data on
the entire PRACSIS population are given for comparison. Patients
with higher CgA values were more likely to be older, to have lower
body mass index, to have clinical evidence of heart failure, a history
of MI, angina, congestive heart failure, or diabetes mellitus; to be
diuretic users, angiotensin-converting enzyme-inhibitor or
angiotensin receptor blocker users, statin users, or aspirin users
(data not shown); and to have a low ejection fraction or low
eGFR. There was no relation between CgA and troponin T or
creatine kinase MB fraction in serum. A signiﬁcant correlation
(rs ¼20.43, P , 0.001) between eGFR and CgA indicated that
renal function inﬂuenced the CgA level. On the other hand, the
lack of correlation between CgA and troponin T values (rs ¼
0.03, P ¼ 0.18) indicated that myocardial necrosis was not a
major explanation for increased CgA levels. There were no signiﬁ-
cant differences in CgA levels between female and male patients.
There was no signiﬁcant interaction between index diagnosis and
CgA regarding outcome. Accordingly, we decided not to analyse
these groups separately.
Chromogranin A and long-term
mortality
During a median follow-up of 92 months (interquartile range 71–
110 months), 389 patients died. CgA serum levels at baseline were
closely associated with long-term, all-cause mortality [hazard ratio
per 1 SD increase in logarithmically transformed CgA levels: 1.57
(1.44–1.70), P , 0.001]. The Kaplan–Meier survival curves by
CgA quartiles are depicted in Figure 1. After adjustment for con-
ventional risk factors, CgA remained independently associated
with mortality [hazard ratio per 1 SD increase in logarithmically
transformed CgA levels: 1.28 (1.15–1.42), P , 0.001] (Table 2).
CgA levels were also an independent predictor of mortality in the
subgroup of patients in whom troponin T levels were available
and adjusted for in addition to the covariates in the ﬁrst model
[n ¼ 1043; HR 1.27 (1.13–1.42), P , 0.001]. In the group where
left ventricular ejection fraction was determined (n ¼ 824), CgA
was as an independent predictor of all-cause mortality after adjust-
ment for conventional cardiovascular risk factors, troponin T levels,
and echocardiographically assessed left ventricular ejection fraction
[HR 1.26 (1.10–1.44), P , 0.001]. In the group where also data
on proBNP were available and additionally adjusted for (n ¼ 709),
a signiﬁcant predictive value of CgA was also noted [HR 1.18
(1.01–1.37), P ¼ 0.04]. Patients with both CgA and proBNP in the
highest quartiles had an especially poor prognosis (Figure 2).
Chromogranin A and non-fatal
cardiovascular events
By univariable analyses, the baseline CgA concentration was strongly
associated with the incidence of heart failure hospitalizations [hazard
ratio 1.54 (1.35–1.76), P , 0.001] and recurrent MI [hazard ratio
1.27 (1.10–1.47), P , 0.001], but not stroke [hazard ratio 1.16
(0.93–1.46), P ¼ 0.19] (Table 2). After adjustment for conventional
risk factors, CgA remained independently associated with the
incidence of heart failure hospitalizations [hazard ratio 1.24
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Table 1 Patient characteristics according to chromogranin A (U/L) quartile
CgA  14.7 (n ¼ 320) CgA 14.8–20.9 (n ¼ 315) CgA 21.0–33.7 (n ¼ 318) CgA .33.7 (n ¼ 315) P-value
a Entire population
b (n ¼ 2258)
Age (years) 60+11 65+10 67+96 8 +9 ,0.001 66+10
Female 89 (28) 98 (31) 90 (28) 102 (32) 0.31 688 (30)
Previous MI 57 (18) 65 (21) 68 (21) 84 (27) 0.002 558 (25)
Previous angina 125 (39) 149 (47) 143 (45) 152 (48) 0.02 1173 (52)
Previous heart failure 14 (4) 26 (8) 19 (6) 43 (14) ,0.001 233 (10)
Previous diabetes 50 (16) 46 (15) 42 (13) 75 (24) 0.01 435 (19)
Previous hypertension (1)
c 134 (42) 118 (38) 109 (34) 138 (44) 0.83 938 (42)
Previous hypercholesterolaemia (1)
c 91 (29) 96 (30) 81 (25) 87 (28) 0.41 665 (30)
Current smoker (20)
c 112 (35) 95 (31) 96 (30) 97 (32) 0.24 648 (30)
ST-elevation MI 137 (43) 121 (38) 134 (42) 139 (44) 0.64 840 (37)
Non-ST-elevation MI 108 (34) 111 (35) 116 (36) 112 (36) 0.54 766 (34)
Unstable angina 75 (23) 83 (26) 68 (21) 64 (20) 0.21 652 (29)
ST-elevation on admission (2)
c 128 (40) 109 (35) 119 (37) 121 (39) 0.77 744 (33)
ST-depression (no elevation) on admission (2)
c 32 (10) 35 (11) 33 (10) 43 (14) 0.11 253 (11)
Q-wave on admission (2)
c 39 (12) 19 (6) 38 (12) 53 (17) 0.01 236 (10)
SBP ,100 mmHg on admission (1)
c 6 (2) 13 (4) 9 (3) 13 (4) 0.23 95 (4)
Heart rate on admission (b.p.m.) (2)
c 76+19 76+22 75+20 77+21 0.94 77+22
CK-MB max (mg/L) 56 (8, 211) 49 (7, 148) 60 (11, 78) 62 (10, 203) 0.36 38 (5, 150)
Troponin T max (mg/L) (225)
c,d 0.8 (0.1, 3.9) 0.8 (0.0, 3.4) 1.2 (0.1, 4.3) 0.8 (0.1, 4.1) 0.18 0.6 (0.0, 3.4)
eGFR (mL/min) (19)
c 82+23 70+20 65+20 56+21 ,0.001 67+24
proBNP (ng/L) (265)
c 1327 (400, 2517) 1551 (572, 3007) 1982 (929, 3572) 2258 (1018, 4307) ,0.001 1772 (702, 3238)
Body mass index (kg/m
2) (32)
c 27.2+4.0 26.3+3.8 25.8+3.7 25.5+4.0 ,0.001 26.3+3.9
Killip class II–IV on admission (2)
c 11 (3) 18 (6) 18 (6) 37 (12) ,0.001 193 (9)
Max Killip class II–IV(2)
c 33 (10) 47 (15) 65 (20) 85 (27) ,0.001 463 (21)
Thrombolysis/primary PCI 109 (34) 99 (31) 100 (31) 107 (34) 0.98 600 (27)
Other PCI or CABG during hospitalization 88 (28) 92 (29) 90 (28) 71 (23) 0.12 669 (30)
LV ejection fraction (%) (278)
c 54+11 54+12 51+12 50+13 ,0.001 52+13
Data expressed as n (%), mean+SD, or median (25th, 75th percentile).
CABG, coronary artery bypass grafting; CK-MB, creatine kinase MB fraction; LV, left ventricular; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.
aActual CgA value used in P-value calculations.
bAll ACS patients admitted without proton pump inhibitors during inclusion period.
cNumber of CgA patients where information was missing.
dThe troponin T level was below detection in 22% of patients (n ¼ 64, 64, 53, 53 in the CgA quartiles given above).
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8(1.04–1.47), P ¼ 0.02], whereas the association with recurrent MI
was attenuated [hazard ratio 1.15 (0.96–1.36), P ¼ 0.12] (Table 2).
In the subgroup where troponin T was available and adjusted for,
CgA was signiﬁcantly associated with both the incidence of heart
failure (P ¼ 0.04) and MI (P ¼ 0.04). However, in the subsample
of patients with echocardiographic data (n ¼ 824), these associ-
ations were attenuated and no longer signiﬁcant after adjustment
for left ventricular ejection fraction (Table 2).
Discussion
The new information obtained from the present study is that
plasma levels of CgA in the acute phase proved to be an indepen-
dent predictor of all-cause mortality in patients with ACSs after
adjustment for conventional risk factors, troponin T levels,
echocardiographically assessed left ventricular ejection fraction,
and proBNP. CgA levels were also associated with heart failure
hospitalizations during follow-up independently of conventional
risk factors, including troponin T. However, in the subsample of
Figure 1 Association between chromogranin A (CgA) levels by
quartiles and all-cause mortality in patients with acute coronary
syndromes.
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Table 2 Associations between chromogranin A concentrations and events during follow-up in patients with acute
coronary syndrome
Endpoint Unadjusted Adjusted
HR
a (95% CI) P-value HR
a (95% CI) P-value
Total cohort (n ¼ 1268)
Mortality 1.57 (1.44, 1.70) ,0.001 1.28 (1.15, 1.42)
b ,0.001
b
Heart failure 1.54 (1.35, 1.76) ,0.001 1.24 (1.04, 1.47)
b 0.02
b
Recurrent MI 1.27 (1.10, 1.47) ,0.001 1.15 (0.96, 1.36)
b 0.12
b
Stroke 1.16 (0.93, 1.46) 0.19 0.96 (0.73, 1.26)
b 0.76
b
With troponin T (n ¼ 1043)
Mortality 1.56 (1.43, 1.71) ,0.001 1.27 (1.13, 1.42)
c ,0.001
c
Heart failure 1.46 (1.26, 1.71) ,0.001 1.23 (1.01, 1.49)
c 0.04
c
Recurrent MI 1.31 (1.12, 1.52) ,0.001 1.21 (1.00, 1.47)
c 0.04
c
Stroke 1.18 (0.92, 1.51) 0.19 0.96 (0.71, 1.29)
c 0.77
c
With troponin T and LV ejection fraction (n ¼ 824)
Mortality 1.56 (1.41, 1.74) ,0.001 1.26 (1.10, 1.44)
d ,0.001
d
Heart failure 1.33 (1.10, 1.61) 0.004 1.12 (0.88, 1.42)
d 0.36
d
Recurrent MI 1.31 (1.10, 1.57) 0.003 1.17 (0.95, 1.45)
d 0.14
d
Stroke 1.16 (0.86, 1.57) 0.34 0.91 (0.62, 1.33)
d 0.62
d
With troponin T, LV ejection fraction, and proBNP (n ¼ 709)
Mortality 1.53 (1.36, 1.72) ,0.001 1.18 (1.01, 1.37)
e 0.04
e
Heart failure 1.34 (1.07, 1.36) 0.009 1.11 (0.85, 1.45)
e 0.45
e
Recurrent MI 1.22 (1.00, 1.49) 0.052 1.10 (0.86, 1.39)
e 0.45
e
Stroke 1.30 (0.95, 1.78) 0.10 1.01 (0.68, 1.48)
e 0.97
e
aHR, hazard ratio per 1 SD pg/mL increase in the natural logarithm of CgA.
bAdjusted for age, gender, index diagnosis, smoking status, prior MI, angina pectoris, diabetes, hypertension, congestive heart failure, heart rate, Killip class (.I) on admission,
eGFR, and peak creatine kinase MB fraction.
cAdjusted for all variables listed in footnote b and troponin T.
dAdjusted for all variables listed in footnote b and troponin T and LV ejection fraction.
eAdjusted for all variables listed in footnote b and troponin T and LV ejection fraction and proBNP.
Chromogranin A in ACS 29patients with echocardiographic data, the association was attenu-
ated and no longer signiﬁcant after adjustment for left ventricular
ejection fraction. Potential reasons for the lack of a statistically
signiﬁcant independent association with heart failure in this sub-
sample include the relative lack of statistical power and the
fact that systolic dysfunction is a very strong predictor of heart
failure. The association between CgA and recurrent MI was also
attenuated after adjustment for conventional risk factors, but was
borderline signiﬁcant in patients in whom troponin T values
were available.
In addition to its strong prognostic merit, several practical features
makeCgAapromisingbiomarkerforclinicaluse,e.g.thatitslonginvivo
half-liferesultsinrelativelyhighcirculatingconcentrations.Thisfeature
simpliﬁes blood collection and pre-analytic handling and makes CgA
less prone to rapid ﬂuctuations in circulating concentrations (low
signal-to-noise ratio) than many other neurohormones.
17 Moreover,
biochemical analysis of CgA can be readily performed using standar-
dized and well-validated, commercially available assays.
22
The two main causes of death in patients with ACSs are (i)
recurrent ischaemic events, manifested as an ACS or sudden
death, and (ii) heart failure, which may cause pulmonary conges-
tion, inadequate tissue perfusion, or malignant arrhythmias.
Although the univariable association between CgA and heart
failure was closer than the associations between CgA and MI in
the total cohort, in adjusted models the associations were of
similar strength, permitting no clear conclusion to be drawn as
to whether the prognostic value of CgA is mediated predominantly
via prediction of heart failure or ischaemic events.
A potential link between the CgA and a propensity to heart
failure development remains to be documented. However, theor-
etical considerations suggest that CgA is not only a marker of
neuroendocrine activity, but may in itself exert harmful actions
on the myocardium. CgA is a pro-hormone with multiple proteo-
lytic cleavage sites,
4 allowing the generation of several peptides
with different actions such as vasodilation,
23,24 negative inotropic
actions,
25 inhibition of catecholamine secretion,
26 and induction
of apoptosis.
27,28 Accordingly, some of the CgA-derived fragments
could have effects of importance for cardiovascular homeostasis
and the heart failure development, including catestatin, a potent
non-competitive inhibitor of catecholamine release.
29 In a knock-
out mouse model, obliteration of CgA gene expression resulted
in decreased size and number of chromafﬁn granules as well as
arterial hypertension and ventricular hypertrophy, whereas trans-
genic expression of human CgA and exogenous injection of
human catestatin restored blood pressure.
30 These ﬁndings
suggest that CgA and catestatin may play a signiﬁcant role in
cardiovascular homeostasis.
The stimulus for CgA production and the pathophysiological
role CgA plays in ACSs remain to be accurately deﬁned. Acute
ischaemia and subsequent left ventricular dysfunction are both
characterized by complex neuroendocrine and immune activation,
and may both represent potential correlates of CgA production.
Accordingly, the magnitude of the CgA response in ACSs may
be related to the initial extent of myocardial injury and subsequent
degree of ventricular dysfunction. It is also conceivable that CgA
production is a compensatory response to the immune activation
associated with ischaemia and heart failure development. Accord-
ingly, in a mouse model, it has recently been demonstrated that
CgA and its amino terminal fragments inhibit tumour necrosis
factor a-induced increase in vascular permeability by preventing
re-arrangement of the cytoskeleton,
31,32 suggesting that CgA
could contribute to the regulation of endothelial barrier function.
The source of increased circulating levels of CgA in ACSs is not
clear. CgA has been detected in the atrial secretory granules con-
taining atrial natriuretic peptide,
33 and recently myocardial pro-
duction of CgA in humans with dilated and hypertrophic
cardiomyopathy has been demonstrated,
11 suggesting that CgA
may be released from the myocardium in conditions characterized
by pressure or volume overload. However, this does not rule out
the possibility that other organs, including the adrenals, may be
contributing sources to increased levels of CgA. Reduced clear-
ance of CgA may also result in higher circulating levels.
34 Arterial
and venous blood sampling across vascular beds will be required
to determine organ-speciﬁc production and clearance of CgA.
Strengths and limitations
The prospective, observational design, long duration of follow-up,
and, in a considerable proportion of patients, echocardiographic
information concerning left ventricular systolic function and
proBNP are all important strengths of the current single-centre
study. In particular, objective measures of left ventricular systolic
function are not commonly obtained or adjusted for in biomarker
substudies of major pharmaceutical multi-centre trials in patients
with ACSs. Limitations include the lack of troponin T, echocardio-
graphic data, and/or proBNP in part of the patients, mainly because
blood sampling was not performed systematically in the early
phase of the study, and because echocardiography was not always
feasible in patients who were discharged early. As data may not
be missing completely at random, we cannot rule out the possibility
of some extent of selection bias. However, given that the hazard
ratio estimates do not vary widely between models, we believe
that the bias is likely to be minor. Moreover, direct comparison of
the hazard ratios of the different multivariate models in Table 2
Figure 2 Association between chromogranin A (CgA) and
pro-B-type natriuretic peptide (proBNP) levels by combined
quartiles (q) and all-cause mortality in patients with acute coron-
ary syndromes.
A.M. Jansson et al. 30should be avoided. There was relatively modest power to detect
associations between CgA and speciﬁc morbidity endpoints.
However, we believe that these limitations will tend to under-
estimate, rather than overestimate, the prognostic value of CgA.
Conclusions
This study shows that plasma CgA levels obtained within the ﬁrst
24 h of admission are independently associated with the incidence
of death in patients with ACS. Clinical use of CgA measurements
for risk stratiﬁcation purposes in patients with ACS must,
however, await conﬁrmatory evidence from other studies.
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Aortoesophageal ﬁstula, a catastrophic complication soon after successful
repair of an aortic dissection type A
Herminia Torrado*, Josep L. Ventura, and Elisabet Farrero
Cardiac Surgery Intensive Care Unit, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona 08907, Spain
* Corresponding author. Tel: þ34 932 607 923, Fax: þ34 932 607 963, Email: 27672hts@comb.es/minuca_t@hotmail.com
A66-year-oldmanwithahistoryofarterialhyperten-
sionunderwentemergencycardiacsurgeryforaortic
dissection type A, diagnosed by a computed tomo-
graphic scan (Panel A) after abdominal pain and
syncope. The lesion was repaired with a Dacron
tubular prosthesis. In the postoperative period, he
improvedhisconditionslowlyundermechanicalven-
tilation and inotropic support. At postoperative day
12, he was awake with minimum inotropic support
and in weaning from mechanical ventilation.
Suddenly, he presented massive haematemesis.
Under the suspicion of an aorto-oesophageal
ﬁstula, an urgent upper gastrointestinal endoscopy
was performed, showing active bleeding at 36 cm
from the dental arcade.
Resuscitation required transfusion of 13 packed
red blood cells, four units of fresh frozen plasma,
and seven units of platelets.
A Sengstaken–Blackmore tube was inserted in
order to contain the bleeding, which was successful
for a while.
After stabilization, an aortogram was performed
(Panels B–D), which revealed contrast leak with
active bleeding in the descending thoracic aorta
from the true lumen to the oesophagus, at the level
of the gastric balloon of the Sengstaken tube which
was placed at the oesophagus (Panel C).
The placement of an endovascular stent graft was
impossible because of the extensive lesions in the
aortic wall.
The patient died 15 h after the initial bleeding, in a situation of refractory shock and persistent bleeding.
Aortoesophageal ﬁstula is an uncommon complication in the early postoperative period of aortic dissection type A, usually fatal as a
result of exsanguinating haemorrhage before assessment and any treatment can be undertaken.
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